Nabriva is a clinical-stage biopharmaceutical company engaged in the research and development of novel antibiotics to treat serious infections, with a focus on the pleuromutilin class of antibiotics. Our goal is to become a fully integrated biopharmaceutical company focused on the research, development and commercialization of novel anti-infective products. The key elements of our strategy to achieve this goal are to:

  • complete Phase 3 clinical development of lefamulin for CABP;
  • maximize the commercial potential of lefamulin for CABP;
  • pursue the continued development of lefamulin in additional indications;
  • advance the development of other pleuromutilin product candidates and possibly compounds in other classes; and
  • evaluate business development opportunities and potential collaborations with other pharmaceutical or biotechnology companies.